Geode Capital Management
KYTX icon

Geode Capital Management’s Kyverna Therapeutics KYTX Stock Holding History

Geode Capital Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.66M Buy
423,826
+157,424
+59% +$1.31M ﹤0.01% 2893
2025
Q4 		$2.51M Sell
266,402
-11,927
-4% -$88.5K ﹤0.01% 3080
2025
Q3 		$1.67M Sell
278,329
-9,272
-3% -$37.1K ﹤0.01% 3240
2025
Q2 		$883K Sell
287,601
-276,373
-49% -$684K ﹤0.01% 3365
2025
Q1 		$1.09M Buy
563,974
+24,292
+5% +$71.8K ﹤0.01% 3277
2024
Q4 		$2.02M Buy
539,682
+96,370
+22% +$462K ﹤0.01% 3119
2024
Q3 		$2.17M Buy
443,312
+70,714
+19% +$545K ﹤0.01% 3097
2024
Q2 		$2.79M Buy
372,598
+200,362
+116% +$3.06M ﹤0.01% 3012
2024
Q1 		$4.28M Buy
+172,236
New +$4.81M ﹤0.01% 2779

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Geode Capital Management's KYTX Position: Q1 2026 in Review

Geode Capital Management increased its Kyverna Therapeutics (KYTX) stake by 59% in Q1 2026, buying an estimated $1.31M and bringing the position to 423,826 shares worth $3.66M. The position accounts for ﹤0.01% of the portfolio, ranked #2893.

Geode Capital Management first reported a position in KYTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $4.28M in Q1 2024. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Geode Capital Management held 423,826 shares of Kyverna Therapeutics worth $3.66M as of Q1 2026.
  • Geode Capital Management bought 157,424 Kyverna Therapeutics shares in Q1 2026, an estimated $1.31M.
  • Kyverna Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #2893 holding.
  • Geode Capital Management first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • Geode Capital Management's Kyverna Therapeutics position peaked at $4.28M in Q1 2024.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.